The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

ZNF217  -  zinc finger protein 217

Homo sapiens

Synonyms: ZABC1, Zinc finger protein 217
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ZNF217

  • CCND1 amplifications were associated with the pharyngeal site in primary carcinomas (P < 0.001), whereas amplifications of ZNF217 were less frequent in pharyngeal carcinomas as compared with primary oral and laryngeal carcinomas (P = 0.02) [1].
  • The amplification of Her2/neu or ZNF217 is closely associated with the stages of breast cancer [2].
  • In multivariate analysis, stage, grade, amount of residual tumor, and ZNF217 amplification showed independent prognostic value (all P < .05) [3].
  • The utility of QuMA is demonstrated in assessment of the extent of deletions of chromosome 2 in leukemias arising in radiation-sensitive inbred SJL mice and in analysis of the association of increased copy number of the putative oncogene ZNF217 with reduced survival duration in ovarian cancer patients [4].
  • In this study we have found that ZNF217 amplification is a frequent event in colon cancer and that the extent of its amplification varies markedly between tumours (range 3-13 copies) [5].

High impact information on ZNF217

  • The putative oncogene ZNF217 (ref. 5) mapped to one peak, and CYP24 (encoding vitamin D 24 hydroxylase), whose overexpression is likely to lead to abrogation of growth control mediated by vitamin D, mapped to the other [6].
  • ZNF217 and NABC1 emerged as strong candidate oncogenes and were characterized in detail [7].
  • ZNF217 is centrally located in the 260-kb common region of amplification, transcribed in multiple normal tissues, and overexpressed in all cell lines and tumors in which it is amplified and in two in which it is not [7].
  • ZNF217 is predicted to encode alternately spliced, Kruppel-like transcription factors of 1,062 and 1,108 aa, each having a DNA-binding domain (eight C2H2 zinc fingers) and a proline-rich transcription activation domain [7].
  • We show that the large zinc finger protein ZNF217 contacts CtBP [8] .
  • Alternative purification schemes of a native ZNF217 multisubunit complex reveal the assembly of complementary co-repressors associated with histone lysine demethylase activity by JARID1B/PLU-1 distinct of specific LSD1/AOF2 -mediated histone lysine demethylation [9].

Biological context of ZNF217


Anatomical context of ZNF217


Associations of ZNF217 with chemical compounds


Other interactions of ZNF217

  • Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma [7].
  • Her2/neu, ZNF217 and c-MYC were found to have a significantly increased copy number in breast cancer cells [2].
  • Of the genes amplified in breast cancer, the BTAK gene was amplified in 21%, the MYBL2 gene in 17%, and the ZNF217 gene in 12.5% of the sporadic tumors [15].
  • Expression levels of PTPN1 and ZNF217 were significantly correlated with their copy-numbers in those primary OCs [16].
  • In univariate analysis, residual tumor, FIGO stage and grade, ZNF217 amplification, and CAS levels predicted outcome (all P < .05) [3].

Analytical, diagnostic and therapeutic context of ZNF217


  1. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Freier, K., Joos, S., Flechtenmacher, C., Devens, F., Benner, A., Bosch, F.X., Lichter, P., Hofele, C. Cancer Res. (2003) [Pubmed]
  2. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization. Shimada, M., Imura, J., Kozaki, T., Fujimori, T., Asakawa, S., Shimizu, N., Kawaguchi, R. Oncol. Rep. (2005) [Pubmed]
  3. CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: Correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression. Peiró, G., Diebold, J., Löhrs, U. Am. J. Clin. Pathol. (2002) [Pubmed]
  4. Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Ginzinger, D.G., Godfrey, T.E., Nigro, J., Moore, D.H., Suzuki, S., Pallavicini, M.G., Gray, J.W., Jensen, R.H. Cancer Res. (2000) [Pubmed]
  5. The candidate oncogene ZNF217 is frequently amplified in colon cancer. Rooney, P.H., Boonsong, A., McFadyen, M.C., McLeod, H.L., Cassidy, J., Curran, S., Murray, G.I. J. Pathol. (2004) [Pubmed]
  6. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Albertson, D.G., Ylstra, B., Segraves, R., Collins, C., Dairkee, S.H., Kowbel, D., Kuo, W.L., Gray, J.W., Pinkel, D. Nat. Genet. (2000) [Pubmed]
  7. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Collins, C., Rommens, J.M., Kowbel, D., Godfrey, T., Tanner, M., Hwang, S.I., Polikoff, D., Nonet, G., Cochran, J., Myambo, K., Jay, K.E., Froula, J., Cloutier, T., Kuo, W.L., Yaswen, P., Dairkee, S., Giovanola, J., Hutchinson, G.B., Isola, J., Kallioniemi, O.P., Palazzolo, M., Martin, C., Ericsson, C., Pinkel, D., Albertson, D., Li, W.B., Gray, J.W. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  8. Specific Recognition of ZNF217 and Other Zinc Finger Proteins at a Surface Groove of C-Terminal Binding Proteins. Quinlan, K.G., Nardini, M., Verger, A., Francescato, P., Yaswen, P., Corda, D., Bolognesi, M., Crossley, M. Mol. Cell. Biol. (2006) [Pubmed]
  9. The ZNF217 oncogene is a candidate organizer of repressive histone modifiers. Banck, M.S., Li, S., Nishio, H., Wang, C., Beutler, A.S., Walsh, M.J. Epigenetics. (2009) [Pubmed]
  10. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Ruthenburg, A.J., Allis, C.D., Wysocka, J. Mol. Cell. (2007) [Pubmed]
  11. Array-based comparative genomic hybridization for the detection of DNA sequence copy number changes in Barrett's adenocarcinoma. Albrecht, B., Hausmann, M., Zitzelsberger, H., Stein, H., Siewert, J.R., Hopt, U., Langer, R., Höfler, H., Werner, M., Walch, A. J. Pathol. (2004) [Pubmed]
  12. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Nonet, G.H., Stampfer, M.R., Chin, K., Gray, J.W., Collins, C.C., Yaswen, P. Cancer Res. (2001) [Pubmed]
  13. Identification of Genes Directly Regulated by the Oncogene ZNF217 Using Chromatin Immunoprecipitation (ChIP)-Chip Assays. Krig, S.R., Jin, V.X., Bieda, M.C., O'geen, H., Yaswen, P., Green, R., Farnham, P.J. J. Biol. Chem. (2007) [Pubmed]
  14. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Huang, G., Krig, S., Kowbel, D., Xu, H., Hyun, B., Volik, S., Feuerstein, B., Mills, G.B., Stokoe, D., Yaswen, P., Collins, C. Hum. Mol. Genet. (2005) [Pubmed]
  15. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Tanner, M.M., Grenman, S., Koul, A., Johannsson, O., Meltzer, P., Pejovic, T., Borg, A., Isola, J.J. Clin. Cancer Res. (2000) [Pubmed]
  16. Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers. Watanabe, T., Imoto, I., Katahira, T., Hirasawa, A., Ishiwata, I., Emi, M., Takayama, M., Sato, A., Inazawa, J. Jpn. J. Cancer Res. (2002) [Pubmed]
WikiGenes - Universities